Tesamorelin

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) comprising the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid moiety conjugated to the N-terminus. This modification confers resistance to dipeptidyl peptidase IV (DPP-IV) enzyme degradation, extending the peptide's stability while preserving its biological activity at the GHRH receptor.

Tesamorelin was developed by Theratechnologies Inc. (Montreal, Canada) and received FDA approval in November 2010 under the brand name Egrifta for a specific and narrow indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — a condition characterized by abnormal body fat redistribution that occurs as a side effect of certain antiretroviral therapies (particularly older nucleoside reverse transcriptase inhibitors and protease inhibitors). A reformulated version, Egrifta SV, received FDA approval in May 2019.

Tesamorelin's FDA approval is for this specific population only. Its use outside of HIV-associated lipodystrophy — including general adult obesity, metabolic syndrome, or age-related body composition changes — is off-label and not FDA-sanctioned. It is important to note that tesamorelin has been rigorously studied in the HIV-lipodystrophy context with large Phase 3 trials, making it the most evidence-backed GHRH analog for any specific body composition indication.

Tesamorelin is available only by prescription and is not commercially sold through compounding pharmacies for off-label indications at the scale seen with sermorelin. Access for non-HIV patients is limited and must go through channels that ensure appropriate prescriber oversight.

Tesamorelin stimulates GH secretion through the same GHRH receptor pathway as endogenous GHRH and sermorelin, with key structural modifications that affect its pharmacology:

• GHRH receptor agonism: Tesamorelin binds to the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating adenylyl cyclase and elevating intracellular cAMP. This triggers GH synthesis and pulsatile secretion from the anterior pituitary.
• DPP-IV resistance: The trans-3-hexenoic acid modification at the N-terminus makes tesamorelin resistant to DPP-IV proteolysis. Native GHRH (and sermorelin) are rapidly cleaved by DPP-IV at the His-Ala bond between positions 2 and 3. Tesamorelin's modification blocks this cleavage, extending its effective biological half-life and duration of GHRH receptor stimulation relative to sermorelin.
• Preserved pituitary feedback: Like sermorelin, tesamorelin stimulates GH release through the pituitary's natural mechanisms, keeping negative feedback by somatostatin and IGF-1 intact. This physiological regulation limits the risk of supraphysiological GH levels.
• GH → IGF-1 → Visceral fat effects: GH secreted in response to tesamorelin stimulates hepatic IGF-1 production. Both GH and IGF-1 promote lipolysis (fat breakdown) in adipose tissue. GH's lipolytic effects are particularly pronounced in visceral adipose tissue (VAT), which expresses high levels of GH receptors — this is the pharmacological basis for tesamorelin's selective effect on abdominal fat in lipodystrophy.

Tesamorelin has a robust Phase 3 evidence base for its approved indication, with multiple large randomized controlled trials.

Phase 3 Trials for HIV-Associated Lipodystrophy

• Falutz et al. 2007 (NEJM, PMID: 17978289): The pivotal Phase 3 RCT enrolled 412 HIV-infected adults with abdominal lipodystrophy (confirmed by CT scan measurement of visceral adipose tissue). Participants received tesamorelin 2 mg daily or placebo for 26 weeks. Primary endpoint: change in VAT by CT scan. Mean VAT reduction: −15.2% with tesamorelin versus +5.0% with placebo (net treatment difference: −20.2%). Triglyceride levels and patient-reported belly appearance outcomes also improved significantly. This trial formed the primary basis for FDA approval.
• Falutz et al. 2010 (JAIDS, PMID: 20009918): Extended 52-week trial confirming durability of VAT reduction with tesamorelin (−20.2% net VAT reduction maintained at 52 weeks) and documenting weight regain upon discontinuation — confirming that continued treatment is required to maintain effects.
• Dhaliwal et al. 2018 (J Acquir Immune Defic Syndr): Examined lipid effects; tesamorelin-treated participants showed significant reductions in triglycerides and improvements in lipid ratios alongside VAT reduction, suggesting cardiometabolic benefits beyond body composition.

Off-Label Evidence: Non-HIV Populations

• Metabolic syndrome / type 2 diabetes: Small studies have explored tesamorelin in non-HIV adults with metabolic syndrome. Lo et al. (2020, Diabetes Care, PMID: 32086266) reported reductions in VAT, liver fat, and improvements in triglycerides in non-HIV adults with abdominal obesity over 26 weeks versus placebo. These findings are relevant to the off-label use question but are exploratory, not definitive.
• Non-alcoholic fatty liver disease (NAFLD): Given tesamorelin's reduction of hepatic fat in HIV patients, studies have explored its potential in NAFLD. Aldous et al. (2020) and subsequent work showed reductions in liver fat by MRS in non-HIV adults, suggesting a potential mechanism beyond lipodystrophy.

Evidence Limitations for Off-Label Use

• Most pivotal trials enrolled exclusively HIV-positive adults with antiretroviral-induced lipodystrophy — a population with distinct metabolic characteristics
• Non-HIV off-label studies are small (typically n=50–150) and short-duration
• VAT reduction efficacy in non-HIV populations appears real but less pronounced than in HIV lipodystrophy
• No large Phase 3 trials exist for tesamorelin in general obesity, anti-aging, or performance contexts

Tesamorelin's safety profile is well-characterized from Phase 3 trial data and post-market experience in the HIV-lipodystrophy population.

Common Adverse Effects

• Injection site reactions (most common): Pain, erythema, pruritis, or induration at the injection site. Reported in approximately 25–30% of participants in Phase 3 trials — the most frequent adverse event.
• Edema / fluid retention: Peripheral edema (swelling of the extremities) from GH-related sodium and water retention, reported in approximately 6–7% of participants.
• Musculoskeletal pain: Myalgia, arthralgia (joint pain), and extremity pain, particularly during dose escalation or at higher effective GH levels.
• Hypesthesia/paresthesia: Tingling or reduced sensation in the extremities, related to carpal tunnel-type nerve compression from fluid retention.

Metabolic Effects

• Glucose metabolism: GH is counter-regulatory to insulin. Tesamorelin modestly increases fasting glucose and insulin resistance. In Phase 3 HIV trials, HbA1c increased by approximately 0.1–0.2% versus placebo. In patients with diabetes or pre-diabetes, closer glucose monitoring is warranted.
• IGF-1 elevation: Tesamorelin elevates serum IGF-1 levels; monitoring is recommended to avoid levels above the upper limit of normal for age and sex.

Serious Adverse Effects and Contraindications

• Active malignancy: Tesamorelin is contraindicated in patients with active malignancy (including hypothalamic/pituitary tumors that could be disrupted by GH axis manipulation) and in individuals with a history of GH-dependent tumors. GH and IGF-1 are known growth factors; stimulating their production in a setting of active cancer is inappropriate.
• Pregnancy: Tesamorelin is classified as FDA Pregnancy Category X (demonstrated fetal risk in animal studies) and is contraindicated during pregnancy.
• Disruption of existing HPA axis tumors: Patients with pituitary or hypothalamic disease who may have residual sensitivity to GHRH should be evaluated carefully before starting tesamorelin.
• Hypersensitivity: Known hypersensitivity to tesamorelin or any formulation excipient is a contraindication.

The following describes the FDA-approved dosing for HIV-associated lipodystrophy. Off-label adult dosing is referenced separately with appropriate caveats.

FDA-Approved Dosing (Egrifta SV)

• Approved dose: 2 mg subcutaneous injection once daily
• Administration site: Abdominal area (abdomen), rotating injection sites; do not inject into scar tissue, bruises, or the umbilicus area
• Reconstitution: Egrifta SV is provided as a lyophilized powder and must be reconstituted with the included sterile water prior to injection
• Timing: Can be administered at any time of day; consistent daily timing improves compliance and IGF-1 monitoring accuracy

Monitoring Recommendations (Approved Use)

• Baseline and follow-up serum IGF-1 levels (every 3–6 months)
• Fasting glucose and HbA1c monitoring, especially in those with risk factors for diabetes
• CT or DXA assessment of VAT to document treatment response

Off-Label Adult Dosing (Exploratory / Not FDA-Approved)

In research studies exploring tesamorelin in non-HIV populations (metabolic syndrome, NAFLD), the dose used is typically the same as the approved dose: 2 mg subcutaneous daily. Off-label prescribing of tesamorelin in the US is legally permissible under physician discretion but uncommon relative to sermorelin or CJC-1295 due to Egrifta's higher cost and prescription complexity.

Cost Considerations

Egrifta SV (branded tesamorelin) carries a high wholesale acquisition cost — typically $3,000–$5,000+ per month for the HIV-lipodystrophy indication — with coverage available through specialty pharmacy channels for HIV patients. For off-label use without insurance coverage, this cost is prohibitive for most patients. Compounded tesamorelin is not widely available through US 503A compounders due to the compound's complexity and the availability of the FDA-approved branded product.

Understanding tesamorelin's position among available GHRH analogs requires examining the key differences in structure, evidence, and regulatory status:

Tesamorelin's full-length GHRH 1-44 analog structure may confer receptor activation properties distinct from the 1-29 analogs (sermorelin, CJC-1295), though whether this translates to clinically meaningful differences in body composition outcomes in non-HIV adults is not established. Its high cost limits broad off-label adoption despite the strongest VAT reduction evidence of any GHRH analog.

One of the most frequently searched questions about tesamorelin is whether it can reduce visceral fat in people without HIV-associated lipodystrophy — general obesity, metabolic syndrome, or age-related abdominal fat accumulation. The honest answer is: probably yes to a meaningful degree, but the evidence is less robust than for the HIV-lipodystrophy indication, and it is not FDA-approved for this use.

What the Evidence Shows

Lo et al. (Diabetes Care, 2020, PMID: 32086266) randomized 60 non-HIV adults with abdominal obesity to tesamorelin 2 mg daily or placebo for 26 weeks. Findings: tesamorelin significantly reduced VAT (−21.6 cm² net treatment difference) and hepatic fat fraction (−20.4% relative reduction) versus placebo. Triglycerides also improved. This is a meaningful result in a small, well-designed study but is not sufficient to support FDA approval or clinical guideline adoption for this indication.

Important Limitations

• VAT reduction in non-HIV patients appears real but may be smaller in relative magnitude than in HIV-lipodystrophy patients, who often have extreme visceral fat accumulation driven by specific metabolic derangements
• Tesamorelin is not a weight-loss drug in the traditional sense — it does not substantially reduce total body weight; it redistributes fat composition by preferentially reducing visceral adipose
• Discontinuation studies confirm that VAT returns toward baseline after stopping treatment — effects are not permanent
• The cost ($3,000–5,000+/month for branded Egrifta) makes off-label use impractical for most patients without HIV lipodystrophy insurance coverage

Clinical Bottom Line

Tesamorelin off-label for visceral fat reduction may be appropriate in specific clinical contexts under physician supervision — particularly for patients with documented visceral adiposity, metabolic syndrome, or NAFLD who have not responded to lifestyle interventions. Any such use should include baseline and follow-up VAT imaging, IGF-1 monitoring, and glucose monitoring, and should be weighed against the drug's cost and contraindications.

• United States: FDA-approved. Egrifta (tesamorelin 2 mg) approved November 2010. Egrifta SV (reformulated lower-volume preparation, same dose) approved May 2019. Both are approved only for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
• Canada: Approved by Health Canada for the same HIV lipodystrophy indication.
• Off-label use: Prescribing tesamorelin for non-HIV adults (general obesity, metabolic syndrome, anti-aging, performance) is off-label and not FDA-approved. It is legally permissible under physician discretion but uncommon in practice due to the drug's cost and limited insurance coverage outside the approved indication.
• Compounding: Unlike sermorelin, tesamorelin is not widely available through 503A compounding pharmacies due to the existence of the FDA-approved branded product and the compound's complexity. Compounded tesamorelin would only be appropriate in situations where the FDA-approved product is not clinically suitable for a specific patient (per FDA compounding regulations).
• Anti-doping: Tesamorelin is prohibited under WADA anti-doping regulations as a GH-axis peptide. Athletes subject to drug testing must be aware of this status.